Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1289570 | 0.87 | NCF1 (0.42) | NCF1KDM4EALDH1A1GLAGAA | |
| SCHEMBL1289665 | 0.86 | KDM4E (0.45) | NCF1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1289667 | 0.86 | HDAC8 (0.46) | NCF1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1289631 | 0.84 | KDM4E (0.43) | NCF1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1289670 | 0.81 | PLA2G2A (0.57) | NCF1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9939070 | 0.81 | CYP11B1 (0.55) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1856468 | 0.76 | KDM4E (0.70) | KDM4ECYP1A2CYP2C19ALDH1A1MAPT | |
| SCHEMBL4033042 | 0.75 | KDM4E (0.59) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1289587 | 0.75 | KDM4E (0.57) | NCF1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1529147 | 0.75 | KDM4E (0.51) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-11-24 | — | — | US | disclosed |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9433618-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | LAUREL THERAPEUTICS LTD. (CN) | 2016-08-04 | — | — | US | disclosed |
| US-9364481-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9315462-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160067254-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-03-10 | — | — | US | disclosed |
| EP-2977050-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | Nivalis Therapeutics, Inc. (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9221810-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-8921562-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140329821-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8785643-B2 | Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2651223-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | NIVALIS THERAPEUTICS, INC. | 2013-10-03 | — | — | US | disclosed |
| EP-2624695-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2012170371-A1 | COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012083165-A1 | NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012048181-A1 | NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340312-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | NCF1 1397/4885KDM4E 2042/4885CYP1A2 110/4885 |
| US-20160279117-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NCF1 1446/4885KDM4E 1484/4885CYP1A2 69/4885 |
| US-20130178499-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | NCF1 1397/4885KDM4E 2042/4885CYP1A2 110/4885 |
| US-20140329821-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NCF1 1446/4885KDM4E 1484/4885CYP1A2 69/4885 |
| US-20160220556-A1 | Novel Substituted Quinoline Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, POR, CBR1 | NCF1 1397/4885KDM4E 2042/4885CYP1A2 110/4885 |
| US-20160067254-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NCF1 1446/4885KDM4E 1484/4885CYP1A2 69/4885 |
| US-20130261123-A1 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors | GSR, CBR1, POR | NCF1 1446/4885KDM4E 1484/4885CYP1A2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.